Metastatic Castration-resistant Prostate Cancer Clinical Trials in Phoenix, Arizona

5 studies are recruiting for metastatic castration-resistant prostate cancer in Phoenix, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

    The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Phoenix, Arizona
    Locations
    132 in total
    Run by
    AstraZeneca

    See if you can join NCT07611110 on ClinicalTrials.gov

  2. A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

    This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Ironwood Cancer & Research Centers, Phoenix, Arizona
    Locations
    236 in total
    Run by
    Pfizer

    See if you can join NCT06629779 on ClinicalTrials.gov

  3. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic, Phoenix, Arizona
    Locations
    33 in total
    Run by
    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

  4. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    Mayo Clinic, Phoenix, Arizona
    Locations
    36 in total
    Run by
    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

  5. A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

    The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Mayo Clinic, Phoenix, Arizona
    Locations
    23 in total
    Run by
    Syncromune, Inc.

    See if you can join NCT06533644 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.